IDEAYA Biosciences (IDYA) News Today $25.48 -0.06 (-0.23%) (As of 10:31 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Quest Partners LLC Purchases 32,884 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Quest Partners LLC lifted its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 2,791.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,062 shares of the company's stock after purchasingNovember 21 at 4:10 AM | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the sixteen brokerages that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, thirteen have assigned a buyNovember 21 at 2:27 AM | marketbeat.comStephens & Co. Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight RecommendationNovember 20 at 12:06 AM | msn.comIdeaya Biosciences initiated with an Overweight at StephensNovember 19 at 4:34 AM | markets.businessinsider.comStephens Initiates Coverage on IDEAYA Biosciences (NASDAQ:IDYA)Stephens assumed coverage on shares of IDEAYA Biosciences in a report on Monday. They set an "overweight" rating and a $51.00 price target on the stock.November 18 at 9:05 AM | marketbeat.comIDEAYA Biosciences Appoints Stu Dorman as Chief Commercial OfficerNovember 18 at 6:00 AM | prnewswire.comIDEAYA Biosciences (NASDAQ:IDYA) Sets New 12-Month Low - Should You Sell?IDEAYA Biosciences (NASDAQ:IDYA) Sets New 1-Year Low - Here's What HappenedNovember 15, 2024 | marketbeat.comPromising Future and Strong Pipeline Drive Buy Rating for IDEAYA BiosciencesNovember 13, 2024 | markets.businessinsider.comIDEAYA Biosciences: Strategic Initiatives and Growth Potential Reinforce Buy RatingNovember 13, 2024 | markets.businessinsider.comIDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D DayNovember 12, 2024 | prnewswire.comIdeaya Biosciences nominates IDE034 as development candidate, exercises optionNovember 11, 2024 | markets.businessinsider.comIDEAYA Biosciences (IDYA) Gets a Buy from RBC CapitalNovember 11, 2024 | markets.businessinsider.comIDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with BiocytogenNovember 11, 2024 | prnewswire.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Position Trimmed by Fiera Capital CorpFiera Capital Corp lowered its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 3.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,289,820 shares of the company's stock after selling 45,590 shares during the peNovember 9, 2024 | marketbeat.comJ.P. Morgan Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)November 8, 2024 | markets.businessinsider.comEquities Analysts Offer Predictions for IDYA FY2024 EarningsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Analysts at Cantor Fitzgerald dropped their FY2024 earnings estimates for IDEAYA Biosciences in a report issued on Tuesday, November 5th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings of ($2.34) per shareNovember 8, 2024 | marketbeat.comGeneral American Investors Co. Inc. Buys New Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)General American Investors Co. Inc. acquired a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 90,000 shares of the company's stock, valued at approNovember 7, 2024 | marketbeat.comFY2024 Earnings Estimate for IDYA Issued By Leerink PartnrsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Leerink Partnrs upped their FY2024 earnings per share (EPS) estimates for shares of IDEAYA Biosciences in a research note issued to investors on Tuesday, November 5th. Leerink Partnrs analyst A. Berens now forecasts that the company will earnNovember 7, 2024 | marketbeat.comFY2024 EPS Estimate for IDEAYA Biosciences Lifted by AnalystIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Investment analysts at Wedbush increased their FY2024 earnings per share estimates for IDEAYA Biosciences in a report released on Monday, November 4th. Wedbush analyst R. Driscoll now expects that the company will earn ($2.40) per share for tNovember 7, 2024 | marketbeat.comIDEAYA Biosciences (IDYA) Gets a Buy from Stifel NicolausNovember 7, 2024 | markets.businessinsider.comPromising Developments in IDEAYA Biosciences: A Catalyst-Rich Future Supports Buy RatingNovember 7, 2024 | markets.businessinsider.comIDEAYA Biosciences (NASDAQ:IDYA) Downgraded by Leerink Partnrs to HoldLeerink Partnrs lowered IDEAYA Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday.November 6, 2024 | marketbeat.comLeerinks downgrades Ideaya Biosciences pending clarity on key programsNovember 6, 2024 | markets.businessinsider.comLeerink Partners Downgrades IDEAYA Biosciences (IDYA)November 6, 2024 | msn.comIDEAYA Biosciences (NASDAQ:IDYA) Shares Down 4.5% - Here's What HappenedIDEAYA Biosciences (NASDAQ:IDYA) Shares Down 4.5% - Should You Sell?November 5, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Releases Earnings Results, Beats Estimates By $0.03 EPSIDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) released its earnings results on Monday. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same quarter in the prior year, the business posted ($0.46) EPS.November 5, 2024 | marketbeat.comLeerink Partners Downgrades IDEAYA Biosciences (NASDAQ:IDYA) to Market PerformLeerink Partners cut IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and set a $27.00 price target for the company. in a report on Tuesday.November 5, 2024 | marketbeat.comWedbush Reiterates "Outperform" Rating for IDEAYA Biosciences (NASDAQ:IDYA)Wedbush reiterated an "outperform" rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a report on Monday.November 5, 2024 | marketbeat.comIDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 4, 2024 | prnewswire.comabrdn plc Purchases Shares of 232,830 IDEAYA Biosciences, Inc. (NASDAQ:IDYA)abrdn plc purchased a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 232,830 shares of the company's stock, valued at approximately $7,376,000. abrdn plc ownedNovember 3, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Hits New 12-Month Low - Here's WhyIDEAYA Biosciences (NASDAQ:IDYA) Reaches New 1-Year Low - Here's What HappenedNovember 1, 2024 | marketbeat.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | prnewswire.comOppenheimer Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)October 29, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)October 29, 2024 | markets.businessinsider.comOppenheimer Reaffirms Outperform Rating for IDEAYA Biosciences (NASDAQ:IDYA)Oppenheimer reissued an "outperform" rating and set a $53.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday.October 29, 2024 | marketbeat.comIdeaya Biosciences announces IND clearance for Werner Helicase inhibitorOctober 28, 2024 | markets.businessinsider.comIDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid TumorsOctober 28, 2024 | prnewswire.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Buy" by AnalystsShares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have been assigned a consensus rating of "Buy" from the fifteen brokerages that are presently covering the stock, MarketBeat.com reports. Fourteen equities research analysts have rated the stock with a buy recommendation and one haOctober 27, 2024 | marketbeat.comOptimistic Buy Rating for IDEAYA Biosciences Amid Promising Drug Development and Strategic PotentialOctober 26, 2024 | markets.businessinsider.comPromising Clinical Data and Strong Safety Profile Support Buy Rating for IDEAYA BiosciencesOctober 26, 2024 | markets.businessinsider.comOptimistic Buy Rating for IDEAYA Biosciences Driven by Promising IDE397 Data and Strong Financial PositionOctober 26, 2024 | markets.businessinsider.comIDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024October 25, 2024 | prnewswire.comIdeaya Biosciences initiated with a Buy at UBSOctober 24, 2024 | markets.businessinsider.comLeerink Partnrs Has Bearish Estimate for IDYA Q3 EarningsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Stock analysts at Leerink Partnrs dropped their Q3 2024 earnings per share (EPS) estimates for IDEAYA Biosciences in a research report issued to clients and investors on Tuesday, October 22nd. Leerink Partnrs analyst A. Berens now forecasts tOctober 24, 2024 | marketbeat.comUBS Group Begins Coverage on IDEAYA Biosciences (NASDAQ:IDYA)UBS Group assumed coverage on shares of IDEAYA Biosciences in a research note on Thursday. They set a "buy" rating and a $50.00 price target for the company.October 24, 2024 | marketbeat.comLogos Global Management LP Acquires New Stake in Bright Minds Biosciences IncOctober 24, 2024 | finance.yahoo.comIDEAYA Biosciences: Promising Prospects for Darovasertib in Uveal Melanoma Neoadjuvant TreatmentOctober 23, 2024 | markets.businessinsider.comIDEAYA Biosciences’ IDE397: Promising Data and Commercial Potential Drive Buy RatingOctober 21, 2024 | markets.businessinsider.comAnalysts Offer Predictions for IDYA FY2024 EarningsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Cantor Fitzgerald issued their FY2024 earnings estimates for IDEAYA Biosciences in a report released on Wednesday, October 16th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings per share of ($2.26) for theOctober 18, 2024 | marketbeat.comCantor Fitzgerald Initiates Coverage on IDEAYA Biosciences (NASDAQ:IDYA)Cantor Fitzgerald started coverage on shares of IDEAYA Biosciences in a research note on Tuesday. They issued an "overweight" rating on the stock.October 15, 2024 | marketbeat.com Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump said you could learn something from this man (Ad)Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. IDYA Media Mentions By Week IDYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IDYA News Sentiment▼0.100.46▲Average Medical News Sentiment IDYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IDYA Articles This Week▼85▲IDYA Articles Average Week Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Catalyst Pharmaceuticals News Cue Biopharma News TherapeuticsMD News Roivant Sciences News Ascendis Pharma A/S News Legend Biotech News Elanco Animal Health News Lantheus News Blueprint Medicines News Nuvalent News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IDYA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
